Skip to main content
Fig. 1 | BMC Nephrology

Fig. 1

From: A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease

Fig. 1

Model Structure for CKD Progression. CKD = chronic kidney disease; ESRD = end-stage renal disease; KDIGO = Kidney Disease Improving Global Outcomes. Note: Patients can reach the death health state from any other health state. G3 includes G3a and G3b. See Additional file 1: Table S1 for a description of CKD stages according to the KDIGO CKD staging system [20]

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us